Development of hepatocellular carcinoma in elderly patients with chronic hepatitis C with or without elevated aspartate and alanine aminotransferase levels. (Q45971639)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Development of hepatocellular carcinoma in elderly patients with chronic hepatitis C with or without elevated aspartate and alanine aminotransferase levels.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19521923

Development of hepatocellular carcinoma in elderly patients with chronic hepatitis C with or without elevated aspartate and alanine aminotransferase levels. (English)

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19521923

1 reference

based on heuristic

inferred from title

chronic hepatitis C

1 reference

based on heuristic

inferred from title

Hiromitsu Kumada

16

object named as

Hiromitsu Kumada

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19521923

Fumitaka Suzuki

2

object named as

Fumitaka Suzuki

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19521923

11

object named as

Kenji Ikeda

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19521923

Masahiro Kobayashi

9

object named as

Masahiro Kobayashi

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19521923

Yoshiyuki Suzuki

4

object named as

Yoshiyuki Suzuki

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19521923

3

object named as

Norio Akuta

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19521923

10

object named as

Yasuji Arase

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19521923

5

object named as

Hitomi Sezaki

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19521923

Yusuke Kawamura

7

object named as

Yusuke Kawamura

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19521923

Mariko Kobayashi

1

object named as

Mariko Kobayashi

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19521923

8

object named as

Tetsuya Hosaka

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19521923

author name string

Hiromi Yatsuji

6

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19521923

Rie Mineta

12

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19521923

Satomi Iwasaki

13

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19521923

Sachiyo Watahiki

14

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19521923

Yuzo Miyakawa

15

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19521923

publication date

1 January 2009

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19521923

Scandinavian Journal of Gastroenterology

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19521923

44

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19521923

8

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19521923

975-983

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19521923

The scientific challenge of hepatitis C.

1 reference

https://api.crossref.org/works/10.1080%2F00365520802588125

21 January 2018

Sex- and age-specific carriers of hepatitis B and C viruses in Japan estimated by the prevalence in the 3,485,648 first-time blood donors during 1995-2000.

1 reference

https://api.crossref.org/works/10.1080%2F00365520802588125

21 January 2018

The prevalence of hepatitis C virus infection in the United States, 1999 through 2002

1 reference

https://api.crossref.org/works/10.1080%2F00365520802588125

21 January 2018

Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group

1 reference

https://api.crossref.org/works/10.1080%2F00365520802588125

21 January 2018

Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups

1 reference

https://api.crossref.org/works/10.1080%2F00365520802588125

21 January 2018

Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening

1 reference

https://api.crossref.org/works/10.1080%2F00365520802588125

21 January 2018

Influence of the genotypes of hepatitis C virus on the severity of recurrent liver disease after liver transplantation

1 reference

https://api.crossref.org/works/10.1080%2F00365520802588125

21 January 2018

Hepatitis C virus genotypes and quantitation of serum hepatitis C virus RNA in liver transplant recipients: relationship with severity of histological recurrence and implications in the pathogenesis of HCV infection

1 reference

https://api.crossref.org/works/10.1080%2F00365520802588125

21 January 2018

Advancing donor liver age and rapid fibrosis progression following transplantation for hepatitis C

1 reference

https://api.crossref.org/works/10.1080%2F00365520802588125

21 January 2018

Treatment of chronic hepatitis C with interferon alone or combined with ribavirin in Japan

1 reference

https://api.crossref.org/works/10.1080%2F00365520802588125

21 January 2018

Chronic hepatitis C virus infection in older adults

1 reference

https://api.crossref.org/works/10.1080%2F00365520802588125

21 January 2018

National prevention of hepatocellular carcinoma in Japan based on epidemiology of hepatitis C virus infection in the general population

1 reference

https://api.crossref.org/works/10.1080%2F00365520802588125

21 January 2018

Interferon-induced prolonged biochemical response reduces hepatocarcinogenesis in hepatitis C virus infection.

1 reference

https://api.crossref.org/works/10.1080%2F00365520802588125

21 January 2018

Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: A long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis.

1 reference

https://api.crossref.org/works/10.1080%2F00365520802588125

21 January 2018

Efficacy of interferon therapy in elderly patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1080%2F00365520802588125

21 January 2018

Efficacy of ribavirin plus interferon-alpha in patients aged >or=60 years with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1080%2F00365520802588125

21 January 2018

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1080%2F00365520802588125

21 January 2018

Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1080%2F00365520802588125

21 January 2018

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

1 reference

https://api.crossref.org/works/10.1080%2F00365520802588125

21 January 2018

Hepatitis C and liver transplantation: enhancing outcomes and should patients be retransplanted

1 reference

https://api.crossref.org/works/10.1080%2F00365520802588125

21 January 2018

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1080%2F00365520802588125

21 January 2018

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

https://api.crossref.org/works/10.1080%2F00365520802588125

21 January 2018

Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1080%2F00365520802588125

21 January 2018

The effect of age on response to therapy with peginterferon alpha plus ribavirin in a cohort of patients with chronic HCV hepatitis including subjects older than 65 yr.

1 reference

https://api.crossref.org/works/10.1080%2F00365520802588125

21 January 2018

Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b.

1 reference

https://api.crossref.org/works/10.1080%2F00365520802588125

21 January 2018

Are elderly patients poor candidates for pegylated interferon plus ribavirin in the treatment of chronic hepatitis C?

1 reference

https://api.crossref.org/works/10.1080%2F00365520802588125

21 January 2018

Age-related response to interferon alfa treatment in women vs men with chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1080%2F00365520802588125

21 January 2018

Identifiers

10.1080/00365520802588125

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19521923

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19521923

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45971639&oldid=1760907893"